Brought to you by 
J&J buys Cougar Biotechnology for about $894mm
19 Aug 2009
Executive Summary
Fresh from initiating the battle to win global rights to Remicade from former marketing partner Schering-Plough, which is in the process of being acquired by Merck, Johnson & Johnson has acquired Cougar Biotechnology (cancer therapeutics) for $43 per share (a 24% premium), or a total of about $894mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J buys Cougar Biotechnology for about $894mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice